Whole-genome sequencing may optimize PARP inhibitor use for cancer patients

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led by Weill Cornell Medicine and NewYork-Presbyterian investigators. The findings suggest further development of this approach is merited.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup